PMV Pharmaceuticals, Inc.
PMVP
$1.38
$0.042.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.44% | -20.46% | -21.85% | -13.06% | -14.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.14% | 1.82% | 10.20% | 8.82% | 11.21% |
| Operating Income | 6.14% | -1.82% | -10.20% | -8.82% | -11.21% |
| Income Before Tax | 9.39% | 1.08% | -6.83% | -25.66% | -27.57% |
| Income Tax Expenses | 101.09% | 100.14% | 86.51% | 86.35% | 86.90% |
| Earnings from Continuing Operations | 6.99% | -28.70% | -32.42% | -60.70% | -65.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.99% | -28.70% | -32.42% | -60.70% | -65.45% |
| EBIT | 6.14% | -1.82% | -10.20% | -8.82% | -11.21% |
| EBITDA | 5.75% | -2.68% | -11.67% | -10.71% | -12.73% |
| EPS Basic | 9.40% | -26.07% | -30.14% | -58.50% | -61.45% |
| Normalized Basic EPS | 4.08% | -5.61% | -16.12% | -15.25% | -16.12% |
| EPS Diluted | 9.40% | -26.07% | -30.14% | -58.50% | -61.45% |
| Normalized Diluted EPS | 4.08% | -5.61% | -16.12% | -15.25% | -16.12% |
| Average Basic Shares Outstanding | 2.68% | 2.28% | 1.86% | 1.40% | 1.96% |
| Average Diluted Shares Outstanding | 2.68% | 2.28% | 1.86% | 1.40% | 1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |